We are live on ! Find out more
MXCT icon

MaxCyte
MXCT

108 hedge funds and large institutions have $452M invested in MaxCyte in 2022 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 39 increasing their positions, 29 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

64% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 11

41% more capital invested

Capital invested by funds: $321M → $452M (+$131M)

34% more repeat investments, than reductions

Existing positions increased: 39 | Existing positions reduced: 29

25% more funds holding in top 10

Funds holding in top 10: 4 → 5 (+1)

6% more funds holding

Funds holding: 102 → 108 (+6)

1.44% more ownership

Funds ownership: 66.98% → 68.42% (+1.4%)

Holders
108
Holders Change
+6
Holders Change %
+5.88%
% of All Funds
1.86%
Holding in Top 10
5
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+25%
% of All Funds
0.09%
New
18
Increased
39
Reduced
29
Closed
11
Calls
$99K
Puts
–
Net Calls
+$99K
Net Calls Change
+$14K

Top Buyers

1
BWLSA
Blue Water Life Science Advisors
California
+$18M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$7.08M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$4.43M
4
BlackRock
BlackRock
New York
+$4.38M
5
Swedbank
Swedbank
Sweden
+$3.9M

Top Sellers

1
CC
Casdin Capital
New York
-$18M
2
Millennium Management
Millennium Management
New York
-$5.19M
3
Goldman Sachs
Goldman Sachs
New York
-$4.65M
4
RI
RTW Investments
New York
-$3.65M
5
Citigroup
Citigroup
New York
-$2.94M
Name Holding Trade Value Shares
Change 		Change in
Stake
Bank of America
26
Bank of America
North Carolina
$4.73M +$3.88M +695,433 +2,149%
NRC
27
North Run Capital
Massachusetts
$3.62M -$457K -82,000 -13%
Lazard Asset Management
28
Lazard Asset Management
New York
$3.15M +$103K +18,503 +4%
Goldman Sachs
29
Goldman Sachs
New York
$2.98M -$4.65M -833,822 -65%
N
30
Nuveen
North Carolina
$2.55M -$41.1K -7,375 -2%
RG
31
Rathbones Group
United Kingdom
$2.5M -$60.1K -10,780 -3%
Allspring Global Investments
32
Allspring Global Investments
North Carolina
$2.18M -$51K -9,135 -3%
Bank of New York Mellon
33
Bank of New York Mellon
New York
$2.17M +$355K +63,691 +24%
JP Morgan Chase
34
JP Morgan Chase
New York
$1.75M +$59.2K +10,608 +4%
BL
35
Bleichroeder LP
New York
$1.62M – – –
PFM
36
Premier Fund Managers
United Kingdom
$1.6M +$1.42M +255,395 New
AMH
37
Apollo Management Holdings
New York
$1.58M – – –
Charles Schwab
38
Charles Schwab
California
$1.5M +$216K +38,797 +20%
RA
39
Royce & Associates
New York
$1.44M +$604K +108,325 +96%
Baillie Gifford & Co
40
Baillie Gifford & Co
United Kingdom
$1.31M +$1.13M +202,800 New
ACA
41
Apis Capital Advisors
New York
$1.3M +$35K +6,271 +3%
Swiss National Bank
42
Swiss National Bank
Switzerland
$1.09M – – –
VF
43
Virtu Financial
New York
$1.01M +$39.8K +7,141 +5%
HSBC Holdings
44
HSBC Holdings
United Kingdom
$910K -$67.7K -12,142 -8%
RhumbLine Advisers
45
RhumbLine Advisers
Massachusetts
$823K +$41.3K +7,403 +6%
Susquehanna International Group
46
Susquehanna International Group
Pennsylvania
$791K +$581K +104,120 +593%
William Blair & Company
47
William Blair & Company
Illinois
$748K -$115K -20,685 -15%
M&T Bank
48
M&T Bank
New York
$686K – – –
New York State Common Retirement Fund
49
New York State Common Retirement Fund
New York
$685K +$76.1K +13,652 +15%
BCM
50
Bridgeway Capital Management
Texas
$658K – – –
1
2
3 4 5

MXCT Hedge Fund Activity: Q3 2022 in Review

108 of the 5,805 institutional investors tracked by Wall St. Rank reported a position in MaxCyte (MXCT) for Q3 2022, worth a combined $452M — up 41% from $321M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new MXCT positions and 11 closed out — a net gain of 7 holders — while 39 added to existing stakes and 29 trimmed.

The largest buyer was Blue Water Life Science Advisors, opening a new position worth an estimated $18M. The largest seller was Casdin Capital, cutting an estimated $18M.

  • 108 institutional investors held MaxCyte (MXCT) as of Q3 2022, up from 102 in Q2 2022.
  • Funds reported $452M of MaxCyte stock for Q3 2022, up 41% quarter-over-quarter.
  • 18 funds opened new MaxCyte positions in Q3 2022 and 11 closed out, a net change of +7 holders.
  • The largest MaxCyte buyer in Q3 2022 was Blue Water Life Science Advisors, an estimated $18M added.
  • The largest MaxCyte seller in Q3 2022 was Casdin Capital, an estimated $18M sold.

Based on aggregated 13F filings for Q3 2022.